Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1
Go back to Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 55.24 +0.54 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.70 | 52 Week High | $77.12 | |||
| Open | $55.39 | 52 Week Low | $49.03 | |||
| Day High | $55.67 | P/E | 35.87 | |||
| Day Low | $54.96 | EPS | $1.54 | |||
| Volume | 2,069,497 | |||||
